Stempoint Capital’s Denali Therapeutics DNLI Stock Holding History

Stempoint Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.19M	Buy	426,561 +7,503	+2%	+$149K	1.57%	22
2025 Q4	$6.92M	Sell	419,058 -1,315,601	-76%	-$22.2M	1.19%	24
2025 Q3	$25.2M	Buy	1,734,659 +1,026,744	+145%	+$14.8M	5.05%	5
2025 Q2	$9.9M	Buy	707,915 +40,837	+6%	+$575K	3.18%	11
2025 Q1	$9.07M	Buy	667,078 +82,750	+14%	+$1.59M	2.89%	12
2024 Q4	$11.9M	Buy	584,328 +302,278	+107%	+$7.74M	2.97%	9
2024 Q3	$8.22M	Buy	282,050 +31,040	+12%	+$769K	2.46%	14
2024 Q2	$5.83M	Buy	+251,010	New	+$4.82M	1.71%	19

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stempoint Capital's DNLI Position: Q1 2026 in Review

Stempoint Capital increased its Denali Therapeutics (DNLI) stake by 1.8% in Q1 2026, buying an estimated $149K and bringing the position to 426,561 shares worth $8.19M. The position accounts for 1.57% of the portfolio, ranked #22.

Stempoint Capital first reported a position in DNLI in Q2 2024 and has held it in 8 quarters since. The position peaked at $25.2M in Q3 2025. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Stempoint Capital held 426,561 shares of Denali Therapeutics worth $8.19M as of Q1 2026.
Stempoint Capital bought 7,503 Denali Therapeutics shares in Q1 2026, an estimated $149K.
Denali Therapeutics made up 1.57% of Stempoint Capital's portfolio in Q1 2026, its #22 holding.
Stempoint Capital first reported a position in Denali Therapeutics in Q2 2024 and has held it in 8 quarters since.
Stempoint Capital's Denali Therapeutics position peaked at $25.2M in Q3 2025.
268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.